丙种球蛋白联合注射用亚胺培南西司他丁钠治疗婴幼儿重症肺炎的临床效果  

Clinical efficacy of gamma globulin combined with imipenem cilastatin sodium for injection in the treatment of severe pneumonia in infants and young children

作　　者：刘文卓 LIU Wen-zhuo(.Pharmacy Department,Jinan Integrated Traditional Chinese and Western Medicine Hospital,Jinan 271100,China)

机构地区：[1]济南市中西医结合医院药学部,271100

出　　处：《中国现代药物应用》2024年第7期34-38,共5页Chinese Journal of Modern Drug Application

摘　　要：目的探讨丙种球蛋白联合注射用亚胺培南西司他丁钠治疗婴幼儿重症肺炎的临床效果。方法68例婴幼儿重症肺炎患儿,依照随机数字表法分成对照组和研究组,各34例。对照组患儿治疗时给予注射用亚胺培南西司他丁钠,研究组患儿治疗时联合应用注射用亚胺培南西司他丁钠和丙种球蛋白。对比两组的临床疗效、不良反应发生率及血清炎性因子[C反应蛋白(CRP)、降钙素原(PCT)]、免疫功能指标(CD^3(+)、CD^4(+)/CD^8(+))、症状评分、肺功能指标[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)]、动脉血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]。结果研究组总有效率100.00%比对照组的85.29%更高(P<0.05)。治疗后,两组CRP、PCT水平均低于治疗前,且研究组CRP(5.89±1.06)mg/L、PCT(0.46±0.15)ng/ml均低于对照组的(7.02±1.27)mg/L、(0.69±0.23)ng/ml(P<0.05)。治疗后,两组咳嗽、咳痰、发热评分均低于治疗前,且研究组咳嗽评分(1.17±0.39)分、咳痰评分(1.06±0.31)分、发热评分(1.16±0.40)分均低于对照组的(1.58±0.43)、(1.52±0.48)、(1.61±0.45)分(P<0.05)。治疗后,两组FEV1、FEV1/FVC、PaO_(2)均高于治疗前,PaCO_(2)低于治疗前,且研究组FEV1、FEV1/FVC、PaO_(2)均高于对照组,PaCO_(2)低于对照组(P<0.05)。治疗后,两组CD^3(+)、CD^4(+)/CD^8(+)均高于治疗前,且研究组CD^3(+)(41.92±2.43)%、CD^4(+)/CD^8(+)(1.89±0.34)均高于对照组的(38.05±2.18)%、(1.52±0.31)(P<0.05)。两组不良反应发生率对比未发现明显差异(P>0.05)。结论在婴幼儿重症肺炎治疗时联合应用注射用亚胺培南西司他丁钠和丙种球蛋白,可更加有效控制患儿的病情,对其炎症反应、免疫功能、肺功能及动脉血气状况均可起到良好的改善作用,且联合用药后的不良反应未增多,用药安全性良好。Objective To explore the clinical efficacy of gamma globulin combined with imipenem cilastatin sodium for injection in the treatment of severe pneumonia in infants and young children.Methods 68 infants and young children with severe pneumonia were divided into a control group and a study group using the random number table method,with 34 cases in each group.The control group was treated with imipenem cilastatin sodium for injection,and the study group was treated with imipenem cilastatin sodium for injection and gamma globulin.Both groups were compared in terms of clinical efficacy,incidence of adverse reactions,serum inflammatory factor indicators[C-reactive protein(CRP)and procalcitonin(PCT)],immune function+indicators(CD3 and CD^4(+)/CD^8(+)),symptom scores,lung function indicators[forced expiratory volume in one second(FEV1)and ratio of FEV1 to forced vital capacity(FEV1/FVC)],and arterial blood gas indicators[arterial partial pressure of oxygen(PaO_(2))and arterial partial pressure of carbon dioxide(PaCO_(2))].Results The total effective rate of 100.00%in the study group was higher than 85.29%in the control group(P<0.05).After treatment,the levels of CRP and PCT in both groups were lower than those before treatment;the study group had CRP of(5.89±1.06)mg/L and PCT of(0.46±0.15)ng/ml,which were lower than(7.02±1.27)mg/L and(0.69±0.23)ng/ml in the control group(P<0.05).After treatment,the scores of cough,sputum and fever in both groups were lower than those before treatment;the study group had cough score of(1.17±0.39)points,sputum score of(1.06±0.31)points and fever score of(1.16±0.40)points,which were lower than(1.58±0.43),(1.52±0.48)and(1.61±0.45)points in the control group(P<0.05).After treatment,FEV1,FEV1/FVC and PaO_(2) in both groups were higher than those before treatment,and PaCO_(2) was lower than that before treatment;the study group had higher FEV1,FEV1/FVC and PaO_(2) than those in the control group,and lower PaCO_(2) than that in the control group(P<0.05).+After treatment,CD3 and CD^4(+

关 键 词：婴幼儿 重症肺炎 注射用亚胺培南西司他丁钠 丙种球蛋白 

分 类 号：R725.6[医药卫生—儿科]